Industry Science
Published in:
Volume 7 / Year 2013 / Issue 1
Volume 7 / Year 2013 / Issue 1
Trabectedin + pegylated liposomal doxorubicin (PLD) is back!
Page: 22-23
Abstract:Oncologists have welcomed the return of pegylated liposomal doxorubicin (PLD) after an 18-month halt in production. Patients with recurrent ovarian cancer benefit from PLD as monotherapy or in combination with… Read More »
